Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005 Paris, France.
Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
J Inorg Biochem. 2019 Sep;198:110752. doi: 10.1016/j.jinorgbio.2019.110752. Epub 2019 Jun 17.
Due to acquired resistance or limitations of the currently approved drugs against cancer, there is an urgent need for the development of new classes of compounds. Among others, there is an increasing attention towards the use of Ru(II) polypyridyl complexes. Most studies in the literature were made on complexes based on the coordination of N-donating bidentate ligands to the ruthenium core whereas studies on 2,2':6', 2″-terpyridine (terpy) coordinating ligands are relatively scare. However, several studies have shown that [Ru(terpy)2] derivatives are able bind to DNA through various binding modes making these compounds potentially suitable as chemotherapeutic agents. Additionally, light irradiation of these compounds was shown to enable DNA cleavage, highlighting their potential use as photosensitizers (PSs) for photodynamic therapy (PDT). In this work, we present the systematic investigation of the potential of 7 complexes of the type [Ru(terpy)(terpy-X)]2+ (X = H (1), Cl (2), Br (3), OMe (4), COOH (5), COOMe (6), NMe2 (7)) as potential chemotherapeutic agents and PDT PSs. Importantly, six of the seven complexes were found to be stable in human plasma as well as photostable in acetonitrile upon continuous light irradiation (480 nm). The determination of the distribution coefficient logP values for the 7 complexes revealed their good water solubility. Complex 7 was found to be cytotoxic in the micromolar range in the dark as well as to have some phototoxicity upon light exposure at 480 nm in non-cancerous retinal pigment epithelium (RPE-1) and cancerous human cervical carcinoma (HeLa) cells. SYNOPSIS: The systematic investigation of the potential of 7 complexes of the type [Ru(terpy)(terpy-X)] (terpy: 2,2':6', 2″-terpyridine; X = H (1), Cl (2), Br (3), OMe (4), COOH (5), COOMe (6), NMe2 (7)) as potential chemotherapeutic agents and photosensitizers for photodynamic therapy is presented.
由于获得性耐药或目前批准的抗癌药物的局限性,迫切需要开发新类别的化合物。其中,人们越来越关注使用 Ru(II) 多吡啶配合物。文献中的大多数研究都是基于 N 供体双齿配体与钌核的配位进行的,而关于 2,2':6', 2″-三联吡啶(terpy)配位配体的研究相对较少。然而,几项研究表明,[Ru(terpy)2] 衍生物能够通过各种结合模式与 DNA 结合,使这些化合物有可能成为潜在的化疗药物。此外,这些化合物的光照射被证明能够使 DNA 断裂,突出了它们作为光动力疗法(PDT)光敏剂(PSs)的潜在用途。在这项工作中,我们系统地研究了 7 种类型的 [Ru(terpy)(terpy-X)]2+(X=H(1)、Cl(2)、Br(3)、OMe(4)、COOH(5)、COOMe(6)、NMe2(7))配合物作为潜在化疗药物和 PDT PSs 的潜力。重要的是,在人类血浆中发现这 7 种配合物中有 6 种是稳定的,并且在连续光照(480nm)下在乙腈中也是光稳定的。7 种配合物的分配系数 logP 值的测定表明它们具有良好的水溶性。在黑暗中,配合物 7 在微摩尔范围内具有细胞毒性,并且在非癌细胞视网膜色素上皮(RPE-1)和癌细胞人宫颈癌细胞(HeLa)中在 480nm 光照射下具有一定的光毒性。